钠-葡萄糖协同转运蛋白2抑制剂：心力衰竭治疗领域的“跨界明星”

SGLT2i: the ‘crossover star’ for the treatment of heart failure

摘要:

近年来钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）在治疗心力衰竭（以下简称心衰）方面取得许多关键性进展，心血管结局研究开启了SGLT2i改善心血管预后的大门，DAPA-HF、EMPEROR-Reduced和SOLOIST-WHF等研究使其适应证扩展到射血分数减低的心衰；同时针对射血分数保留的心衰的临床研究也正在进行中。相信未来会有更多SGLT2i造福心衰患者的循证依据。

Abstract:

Great progress has been made in the treatment of heart failure with sodium-dependent glucose transporter 2 inhibitor (SGLT2i) in the recent years. The outcome studies in the field of cardiovascular diseases have opened the door for SGLT2i to improve cardiovascular prognosis. DAPA-HF, EMPEROR-Reduced, SOLOIST-WHF and other pivotal trials have extended the indications of SGLT2i to heart failure with reduced ejection fraction. The clinical studies on the management of heart failure with preserved ejection fraction with SGLT2i are also in progress. It is believed that there will be more evidence to support the benefits of SGLT2i for patients with heart failure in the future.